Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
|Podcasts|November 11, 2020
Dr. Amy Krambeck discusses 90-day trial of disposable ureteroscope
Author(s)Urology Times staff
On the latest episode of the Speaking of Urology podcast, Dr. Amy Krambeck discusses her recent study evaluating the Axis single-use ureteroscope.
Advertisement
This episode’s guest is Amy E. Krambeck, MD. She discusses a recent Urology Practice paper, "Initial Experience With a Novel Single Use Disposable Ureteroscopy: A Prospective Single Arm 90-day Trial of the Axis Ureteroscope," for which she served as a study author. Krambeck is the Michael O. Koch Professor of Urology at Indiana University School of Medicine, Indianapolis.
Advertisement
Related to this article
The phase 1 study is intended to characterize the safety, tolerability, and feasibility of intravesical administration of UGN-501.
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how work force gaps may affect comprehensive infertility evaluations.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
A recap of the FDA submissions and regulatory decisions in urology from October 2026.
Advertisement
Advertisement
Trending on Urology Times
1
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
2
Infertility care: Examining geographic gaps in access
3
Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide
4
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
5